Selected for Nucleate Activator 2026 Cohort Finalist•Selected for Nucleate Activator 2026 Cohort Finalist•Selected for Nucleate Activator 2026 Cohort Finalist•Selected for Nucleate Activator 2026 Cohort Finalist•
Make the resistance
predictable.
We use a proprietary Deep Mutational Scanning (DMS) engine to map the complete resistance landscape of cancer targets.
Partner with us
De-risk your drug discovery pipeline with our predictive resistance engine.